Anti-Mouse/Human KLRG-1 – DyLight® 594

Anti-Mouse/Human KLRG-1 – DyLight® 594

Product No.: K163

[product_table name="All Top" skus="K163"]

- -
- -
Clone
2F1
Target
KLRG-1
Formats AvailableView All
Product Type
Hybridoma Monoclonal Antibody
Alternate Names
KLRG1, 2F1, MAFA
Isotype
Syrian Hamster IgG
Applications
FC
,
ICC
,
IP
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human/Mouse
Host Species
Syrian Hamster
Immunogen
IL-2-activated NK cells (A-LAK cells) from B6 (H-2b) mice
Product Concentration
0.2 mg/ml
Formulation
This DyLight® 594 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
State of Matter
Liquid
Storage and Handling
This DyLight® 594 conjugate is stable when stored at 2-8°C. Do not freeze.
For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2 – 8° C Wet Ice
Excitation Laser
Red Laser (590 nm)
Additional Applications Reported In Literature ?
FC,
WB,
IP,
ICC
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
2F1 activity is directed against mouse and human KLRG1.
Background
Killer cell lectin-like receptor G1 (KLRG1) is a transmembrane glycoprotein with an extracellular C-type lectin-like domain and a cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM)1. KLRG1 plays an inhibitory role in human NK and T cells2 and is frequently used as a marker of cellular differentiation, with memory cells and highly differentiated end-stage cells having a significantly higher percentage of expression than differentiating cells2. Additionally, the proportion of CD8+ T cells expressing KLRG1 is age-related, increasing from ~ 40% of the CD8+ T cell pool in young adults to 90% in individuals over 65. KLRG1 is known to bind E-, N-, and R-cadherin1, 2. Cadherin interactions are generally involved in cell-to-cell adhesion and additionally, KLRG1/E-cadherin interactions are involved in immune control2.

2F1 was generated by immunizing Syrian hamsters with IL-2 activated NK (A-LAK) cells from B6 (H-2b) mice3. Popliteal lymph node cells were fused to murine myeloma P3X63Ag.8.653 cells and hybridomas screened for antibodies specific to A-LAK cells.

Antibody 2F1 was used to show that KLRG1 is indirectly upregulated by expression of MHC class I molecules in an interaction affected by class I-specific Ly49 inhibitory receptors and was also used to show that KLRG1 expression is modulated by SHP-1 3 . Additionally, 2F1 was used to identify the KLRG1 mouse homolog and show that it is not expressed on mouse mast cells 4.
Antigen Distribution
KLRG1 is expressed by subsets of natural killer cells and a small fraction of T cells but not by other lymphohematopoietic cells in both mouse and human.
Ligand/Receptor
E-, N-, R- cadherins
NCBI Gene Bank ID
UniProt.org
Research Area
Biomarker
.
Cancer
.
Immunology

References & Citations

1. Borys SM, Bag AK, Brossay L, et al. Front Immunol. 13:894508. 2022.
2. Henson SM, Akbar AN. Age (Dordr). 31(4):285-291. 2009.
3. Corral L, Hanke T, Vance RE, et al. Eur J Immunol. 30(3):920-930. 2000.
4. Hanke T, Corral L, Vance RE, et al. Eur J Immunol. 28(12):4409-4417. 1998.
5. Robbins SH, Nguyen KB, Takahashi N, et al. J Immunol. 168(6):2585-2589. 2002.
6. Kieckbusch J, Gaynor LM, Moffett A, et al. Nat Commun. 5:3359. 2014.
7. Tiemessen MM, Baert MR, Kok L, et al. J Immunol. 193(11):5480-5487. 2014.
8. Menendez CM, Jinkins JK, Carr DJ. J Immunol. 197(4):1262-1275. 2016.
9. Graham JB, Swarts JL, Lund JM. Curr Protoc Mouse Biol. 7(4):221-235. 2017.
10. Li Q, Li D, Zhang X, et al. Immunity. 48(2):258-270.e5. 2018.
11. Yasuda K, Kitagawa Y, Kawakami R, et al. Nat Commun. 10(1):549. 2019.
12. Garg G, Muschaweckh A, Moreno H, et al. Cell Rep. 26(7):1854-1868.e5. 2019.
13. Li A, Herbst RH, Canner D, et al. Cell Rep. 29(10):2998-3008.e8. 2019.
14. Sidwell T, Liao Y, Garnham AL, et al. Nat Commun. 11(1):252. 2020.
15. Vasanthakumar A, Chisanga D, Blume J, et al. Nature. 579(7800):581-585. 2020.
16. Huang RY, Francois A, McGray AR, et al. Oncoimmunology. 6(1):e1249561. 2016.
17. Zhao M, Shao F, Yu D, et al. Nat Commun. 13(1):7600. 2022.
Flow Cytometry
ICC
Immunoprecipitation Protocol
General Western Blot Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.